On September 11, 2026, Onconetix, Inc. entered into a Grid Promissory Note with Realbotix, LLC, providing for a strategic bridge financing facility. The agreement allows Onconetix to make available loans to Realbotix with an aggregate principal amount of up to $5.0 million. An initial advance of $2.5 million was made on September 11, 2026.
The proceeds of the loans are to be used by Realbotix for general corporate and working capital purposes. The Note is an unsecured obligation of Realbotix and matures on September 11, 2027. The facility is non-interest bearing prior to the earlier of the closing of the Share Exchange Agreement or its termination. If the Share Exchange Agreement is terminated, interest will accrue on the outstanding principal balance at a rate of 12% per annum until the Note is paid.
The financing is connected to the Share Exchange Agreement signed by Onconetix with Realbotix, Realbotix Corp., and Simulacra Corporation on February 11, 2026. Under this agreement, Onconetix intends to acquire all issued and outstanding equity interests of Realbotix in exchange for newly issued shares of Onconetix common stock. The closing of this transaction is subject to customary conditions, including Onconetix having at least $12.5 million in Net Cash at closing.
Upon the closing of the Share Exchange Agreement, the Note and all obligations under it will be automatically cancelled and discharged in full. Additionally, the Net Cash required at closing will be reduced by the total principal advanced under the Note plus an additional $500,000. Realbotix Corp. has guaranteed Realbotix’s obligations under the Note via a Guaranty of Payment dated September 11, 2026.
